Browse by author
Lookup NU author(s): Dr Steven Young-Min, Emeritus Professor Tim Cawston
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background-Excess tissue matrix accumulates in systemic sclerosis (SSc), accounting for both visceral and dermal fibrosis. It is suggested that decreased serum levels of matrix metalloproteinases (MMPs) or increased levels of tissue inhibitors of matrix metalloproteinases (TIMPs) may account for this matrix accumulation. Objective-To measure serum levels of tissue inhibitors of metalloproteinases, TIMP-1, TIMP-2, and collagenase-1 (MMP-1), in patients with diffuse cutaneous systemic sclerosis (dcSSc), limited cutaneous systemic sclerosis (1cSSc), primary Raynaud's phenomenon (RP), and in normal controls. Methods-Serum samples from patients with dcSSc (n=83), 1cSSc (n=87), RP (n=80), and normal controls (n=98) were analysed using enzyme linked immunosorbent assays (ELISAs) for total TIMP-1, TIMP-2, and MMP-1. Results from each assay were analysed by the Kruskal-Wallis test. Dunn's multiple comparison posttest was then applied between groups. Results-TIMP-1 levels were significantly raised in dcSSc and 1cSSc groups compared with the RP group and normal controls (p <0.01 to p <0.001). In the dcSSc group, TIMP-1 levels were significantly higher in early disease (<2 years) than in late stage disease (>4 years) (p <0.05). This was not found for the 1cSSc group. Serum TIMP-2 and MMP-1 levels in dcSSc and 1cSSc did not differ significantly from those in normal controls. Increased levels of TIMPs were not convincingly associated with organ disease. No assay result correlated with autoantibody status (anti-topoisomerase 1 (anti-Scl-70), anticentromere antibody, or anti-RNA polymerase). No significant differences in serum TIMP-1, TIMP-2, or MMP-1 levels were shown in the RP group compared with normal controls. Conclusions-Raised TIMP-1 levels in the SSc groups support the hypothesis that matrix accumulation occurs in SSc at least in part owing to decreased degradation. Moreover, the variation in TIMP-1 levels between the early and late disease stages of dcSSc seems to reflect the early progressive course of dermal fibrosis seen clinically. The expected reduction in serum MMP-1 levels in the SSc groups was not found. This suggests that tissue matrix accumulation is due to increased inhibitors rather than to decreased MMPs.
Author(s): Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE
Publication type: Article
Publication status: Published
Journal: Annals of the Rheumatic Diseases
Year: 2001
Volume: 60
Issue: 9
Pages: 846-851
ISSN (print): 0003-4967
ISSN (electronic): 1468-2060
Publisher: BMJ Group
URL: http://ard.bmj.com/cgi/content/abstract/60/9/846
